Home / Pharmaceutical / Pfenex Inc. - Product Pipeline Review - 2015

Pfenex Inc. - Product Pipeline Review - 2015

Published: Nov 2015 | No Of Pages: 37 | Published By: Global Markets Direct

Pfenex Inc. - Product Pipeline Review - 2015


Global Markets Direct's, 'Pfenex Inc. - Product Pipeline Review - 2015', provides an overview of the Pfenex Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Pfenex Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.


- The report provides brief overview of Pfenex Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Pfenex Inc.'s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Pfenex Inc.'s pipeline products

Reasons to buy

- Evaluate Pfenex Inc.'s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Pfenex Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Pfenex Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Pfenex Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Pfenex Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Pfenex Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table of Contents 2
List of Tables 5
List of Figures 5
Arrowhead Research Corporation Snapshot 6
Arrowhead Research Corporation Overview 6
Key Information 6
Key Facts 6
Arrowhead Research Corporation - Research and Development Overview 7
Key Therapeutic Areas 7
Arrowhead Research Corporation - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Pipeline Products - Partnered Products 11
Partnered Products/Combination Treatment Modalities 12
Arrowhead Research Corporation - Pipeline Products Glance 13
Arrowhead Research Corporation - Clinical Stage Pipeline Products 13
Phase II Products/Combination Treatment Modalities 13
Phase I Products/Combination Treatment Modalities 14
Arrowhead Research Corporation - Early Stage Pipeline Products 15
Preclinical Products/Combination Treatment Modalities 15
Arrowhead Research Corporation - Drug Profiles 16
ARC-520 16
Product Description 16
Mechanism of Action 16
R&D Progress 16
Product Description 18
Mechanism of Action 18
R&D Progress 18
Antisense RNAi Oligonucleotide for Extra-hepatic Disease 19
Product Description 19
Mechanism of Action 19
R&D Progress 19
ARC-521 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
Product Description 21
Mechanism of Action 21
R&D Progress 21
Product Description 22
Mechanism of Action 22
R&D Progress 22
ARCF-12 23
Product Description 23
Mechanism of Action 23
R&D Progress 23
Peptide for Oncology 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
Peptide to Inhibit CRKL for Leukemia 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Peptide to Inhibit GRP-78 for Melanoma 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Peptide to Inhibit Hemofiltrate CC Chemokine for Metastatic Liver Cancer 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
Peptide to Inhibit Tubulin for Oncology 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
RNA Interference for Hepatocellular carcinoma 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
RNAi Oligonucleotides for Hepatitis C 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Arrowhead Research Corporation - Pipeline Analysis 31
Arrowhead Research Corporation - Pipeline Products by Target 31
Arrowhead Research Corporation - Pipeline Products by Route of Administration 32
Arrowhead Research Corporation - Pipeline Products by Molecule Type 33
Arrowhead Research Corporation - Pipeline Products by Mechanism of Action 34
Arrowhead Research Corporation - Recent Pipeline Updates 35
Arrowhead Research Corporation - Dormant Projects 43
Arrowhead Research Corporation - Discontinued Pipeline Products 44
Discontinued Pipeline Product Profiles 44
CALAA-01 44
Arrowhead Research Corporation - Locations And Subsidiaries 45
Head Office 45
Other Locations & Subsidiaries 45
Appendix 47
Methodology 47
Coverage 47
Secondary Research 47
Primary Research 47
Expert Panel Validation 47
Contact Us 47
Disclaimer 48

Bavarian Nordic A/S, Key Information 5
Bavarian Nordic A/S, Key Facts 5
Bavarian Nordic A/S - Pipeline by Indication, 2015 7
Bavarian Nordic A/S - Pipeline by Stage of Development, 2015 8
Bavarian Nordic A/S - Monotherapy Products in Pipeline, 2015 9
Bavarian Nordic A/S - Partnered Products in Pipeline, 2015 10
Bavarian Nordic A/S - Partnered Products/ Combination Treatment Modalities, 2015 11
Bavarian Nordic A/S - Out-Licensed Products in Pipeline, 2015 12
Bavarian Nordic A/S - Out-Licensed Products/ Combination Treatment Modalities, 2015 13
Bavarian Nordic A/S - Phase III, 2015 14
Bavarian Nordic A/S - Phase II, 2015 15
Bavarian Nordic A/S - Phase I, 2015 16
Bavarian Nordic A/S - Preclinical, 2015 17
Bavarian Nordic A/S - Pipeline by Target, 2015 27
Bavarian Nordic A/S - Pipeline by Route of Administration, 2015 28
Bavarian Nordic A/S - Pipeline by Molecule Type, 2015 29
Bavarian Nordic A/S - Recent Pipeline Updates, 2015 30
Bavarian Nordic A/S - Dormant Developmental Projects,2015 36
Bavarian Nordic A/S - Discontinued Pipeline Products, 2015 37
Bavarian Nordic A/S, Other Locations 38
Bavarian Nordic A/S, Subsidiaries 38

Pfenex Inc. - Pipeline by Top 10 Indication, 2015 7
Pfenex Inc. - Pipeline by Stage of Development, 2015 8
Pfenex Inc. - Monotherapy Products in Pipeline, 2015 9
Pfenex Inc. - Pipeline by Top 10 Target, 2015 28
Pfenex Inc. - Pipeline by Top 10 Route of Administration, 2015 29
Pfenex Inc. - Pipeline by Top 10 Molecule Type, 2015 30
Pfenex Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 31

Choose License Type
Contact Information
24/7 Research Support
Phone: +1-855-455-8662
Get in Touch with us
join us on Facebook
Follow us on Twitter
Follow us on LinkedIn
Add us on Google +